Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.
Department of General Surgery, University of Kansas Medical Center, Kansas City, Kansas.
Cancer Res. 2019 Apr 1;79(7):1681-1695. doi: 10.1158/0008-5472.CAN-18-2602. Epub 2019 Jan 23.
Metastasis is a major cause of cancer-related deaths. A dearth of preclinical models that recapitulate the metastatic microenvironment has impeded the development of therapeutic agents that are effective against metastatic disease. Because the majority of solid tumors metastasize to the lung, we developed a multicellular lung organoid that mimics the lung microenvironment with air sac-like structures and production of lung surfactant protein. We used these cultures, called primitive lung-in-a-dish (PLiD), to recreate metastatic disease using primary and established cancer cells. The metastatic tumor-in-a-dish (mTiD) cultures resemble the architecture of metastatic tumors in the lung, including angiogenesis. Pretreating PLiD with tumor exosomes enhanced cancer cell colonization. We next tested the response of primary and established cancer cells to current chemotherapeutic agents and an anti-VEGF antibody in mTiD against cancer cells in two-dimensional (2D) or 3D cultures. The response of primary patient-derived colon and ovarian tumor cells to therapy in mTiD cultures matched the response of the patient in the clinic, but not in 2D or single-cell-type 3D cultures. The sensitive mTiD cultures also produced significantly lower circulating markers for cancer similar to that seen in patients who responded to therapy. Thus, we have developed a novel method for lung colonization , a final stage in tumor metastasis. Moreover, the technique has significant utility in precision/personalized medicine, wherein this phenotypic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent, thereby increasing the probability of response to treatment while reducing unnecessary side effects. SIGNIFICANCE: A lung organoid that exhibits characteristics of a normal human lung is developed to study the biology of metastatic disease and therapeutic intervention.
转移是癌症相关死亡的主要原因。缺乏能够重现转移性微环境的临床前模型,阻碍了针对转移性疾病的治疗药物的发展。由于大多数实体瘤转移到肺部,我们开发了一种多细胞肺类器官,它具有气囊样结构和肺表面活性蛋白的产生,模拟了肺部微环境。我们使用这些培养物,称为原始肺类器官(PLiD),使用原代和已建立的癌细胞重现转移性疾病。转移性肿瘤类器官(mTiD)培养物类似于肺部转移性肿瘤的结构,包括血管生成。用肿瘤外泌体预处理 PLiD 可增强癌细胞定植。接下来,我们在 mTiD 中测试了原代和已建立的癌细胞对当前化疗药物和抗 VEGF 抗体的反应,以及在二维(2D)或 3D 培养物中对癌细胞的反应。原发性患者来源的结肠和卵巢肿瘤细胞在 mTiD 培养物中的治疗反应与患者在临床中的反应相匹配,但与 2D 或单细胞类型 3D 培养物中的反应不匹配。敏感的 mTiD 培养物也产生了与对治疗有反应的患者相似的明显较低的循环癌症标志物。因此,我们开发了一种新的方法用于肺部定植,这是肿瘤转移的最后阶段。此外,该技术在精准/个性化医学中具有重要的应用价值,其中这种表型筛选可以与当前的 DNA 药物遗传学相结合,以确定理想的治疗药物,从而增加对治疗的反应概率,同时减少不必要的副作用。意义:开发了一种具有正常人类肺特征的肺类器官,用于研究转移性疾病和治疗干预的生物学。